Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Takeda Pharmaceutical Co Ltd And Zinfandel Pharmaceuticals Ltd Initiate Phase 3 TOMMORROW Trial Of AD-4833 For The Delay Of Onset Of Mild Cognitive Impairment Due To Alzheimer's Disease


Monday, 26 Aug 2013 11:40am EDT 

Takeda Pharmaceutical Co Ltd And its partner, Zinfandel Pharmaceuticals Ltd announced the initiation of TOMMORROW, a global Phase 3 clinical trial investigating a genetic-based biomarker risk assignment algorithm (risk assignment algorithm) to predict risk of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) within a five year period and to evaluate the efficacy of the investigational low dose pioglitazone (designated AD-4833 for this use) in delaying the onset of MCI due to AD in cognitively normal individuals at high risk as determined by the risk assignment algorithm. 

Company Quote

4663.0
8.0 +0.17%
11 Jul 2014